Factors associated with underlying malignancy in a retrospective cohort of 121 Patients with dermatomyositis

Medicine

Volumn 88, Issue 2, 2009, Pages 91-97

  Fardet, Laurence ^a,b,d   Dupuy, Alain ^a,b   Gain, Murielle ^b,c   Kettaneh, Adrien ^b,c   Ch̃rin, Patrick ^b,c   Bachelez, Herṽ ^a,b   Dubertret, Louis ^a,b   Lebbe, Celeste ^a,b   Morel, Patrice ^a,b   Rybojad, Michel ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d Service de Médecine Interne AP HP Hôpital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C4;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONFIDENCE INTERVAL; DERMATOMYOSITIS; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SKIN NECROSIS; SYMPTOMATOLOGY; AGE; CLINICAL TRIAL; FRANCE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NAIL DISEASE; NECROSIS; NEOPLASM; PARANEOPLASTIC SYNDROME; PATHOLOGY; SKIN;

ADULT; AGE FACTORS; AGED; COMPLEMENT C4; DERMATOMYOSITIS; ERYTHEMA; FEMALE; FRANCE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAIL DISEASES; NECROSIS; NEOPLASMS; PARANEOPLASTIC SYNDROMES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SKIN; YOUNG ADULT;

EID: 63249114080     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e31819da352     Document Type: Article

References (42)

1. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol. 1995;22:1300-1303.
2. Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med. 1976;84:68-76.
3. Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Revuz J, Touraine R. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol. 1990;126:633-637.
4. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-347.
5. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403-407.
6. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134:1087-1095.
7. Callen JP. When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer? Arch Dermatol. 2002;138:969-971.
8. Callen JP. The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol. 1982;6:253-259.
9. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol. 2001;144:825-831.
10. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer associated myositis. Ann Rheum Dis. 2007;66:1345-1349.
11. Dalakas MC, Hohlfed R. Polymyositis and dermatomyositis. Lancet. 2003;362:971-982.
12. Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004;83:35-42.
13. Feldman D, Hochberg MC, Zizic TM, Stevens MB. Cutaneous vasculitis in adult polymyositis/dermatomyositis. J Rheumatol. 1983;10:85-89.
14. Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med. 1986;80:329-332.
15. Fust G, Miszlay Z, Czink E, Varga L, Paloczi K, Szegedi G, Hollan SR. C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance. Immunol Lett. 1987;14:255-259.
16. Fust G, Czink E, Minh D, Miszlay Z, Varga L, Hollan SR. Depressed classical complement pathway activities in chronic lymphocytic leukaemia. Clin Exp Immunol. 1985;60:489-95.
17. Gallais V, Crickx B, Belaich S. [Prognostic factors and predictive signs of malignancy in adult dermatomyositis]. Ann Dermatol Venereol. 1996;123:722-726.
18. Greer JM, Longley S, Edwards NL, Elfenbein GJ, Panush RS. Vasculitis associated with malignancy. Experience with 13 patients and literature review. Medicine (Baltimore). 1988;67:220-230.
19. Hidano A, Kaneko K, Arai Y, Kikuchi R. Survey of the prognosis for dermatomyositis, with special reference to its association with malignancy and pulmonary fibrosis. J Dermatol. 1986;13:233-241.
20. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96-100.
21. Hunger RE, Durr C, Brand CU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology. 2001;202:123-126.
22. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum. 2002;46:741-744.
23. La Montagna G, Manzo C, Califano E, Tirri R. Absence of elevated creatine kinase in dermatomyositis does not exclude malignancy. Scand J Rheumatol. 1988;17:73-74.
24. Lipskie TL. A summary of cancer screening guidelines. Chronic Dis Can. 1998;19:112-130.
25. Maoz CR, Langevitz P, Livneh A, Blumstein Z, Sadeh M, Bank I, Gur H, Ehrenfeld M. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum. 1998;27:319-324.
26. Marie I, Hachulla E, Cherin P, Hellot MF, Herson S, Levesque H, Hatron PY Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum. 2005;53:155-165.
27. Marie I, Hachulla E, Hatron P-Y, Hellot M-F, Levesque H, Devulder B, Courtois H. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230-2237.
28. Mautner GH, Grossman ME, Silvers DN, Rabinowitz A, Mowad CM, Johnson BL Jr. Epidermal necrosis as a predictive sign of malignancy in adult dermatomyositis. Cutis. 1998;61:190-194.
29. Oddis CV, Conte CG, Steen VD, Medsger TA Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol. 1990;17:1329-1334.
30. Pignone A, Fiori G, Del Rosso A, Generini S, Matucci-Cerinic M. The pathogenesis of inflammatory muscle disease: on the cutting edge among the environment, the genetic background, the immune response and the dysregulation of apoptosis. Autoimmun Rev. 2002;1:226-232.
31. Ponyi A, Constantin T, Garami M, Andras C, Tallai B, Vancsa A, Gergely L, Danko K. Cancer-associated myositis: clinical features and prognostic signs. Ann N YAcad Sci. 2005;1051:64-71.
32. Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, Calvo-Alen J, Jimenez-Alonso J, Micó ML, Beltran J, Belenguer R, Pallares L; GEMESS Study Group. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87:210-219.
33. Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia. 1996;10:1509-1513.
34. Sparsa A, Liozon E, Herrmann F, Ly K, Lebrun V, Soria P, Loustaud-Ratti V, Bouyssou-Gauthier ML, Boulinguez S, Bedane C, Jauberteau MO, Vidal E, Bonnetblanc JM. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol. 2002;138:885-890.
35. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 2001;85:41-45.
36. Sunnenberg TD, Kitchens CS. Dermatomyositis associated with malignant melanoma: parallel occurrence, remission, and relapse of the two processes in a patient. Cancer. 1983;51:2157-2158.
37. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65:796-803.
38. Vargas-Leguas H, Selva-O'Callaghan A, Campins-Marti M, Hermosilla Perez E, Grau-Junyent JM, Martinez Gomez X, Vaque Rafart J. [Polymyositis- dermatomyositis: incidence in Spain (1997-2004)]. Med Clin (Barc). 2007;129:721-724.
39. Verducci MA, Malkasian GD, Friedman SJ, Winkelmann RK. Gynecologic carcinoma associated with dermatomyositis-polymyositis. Obstet Gynecol. 1984;64:695-698.
40. Weitoft T. Occurrence of polymyositis in the county of Gavleborg, Sweden. Scand J Rheumatol. 1997;26:104-106.
41. Whitmore SE, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine (Baltimore). 1994;73:153-160.
42. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Revision; Version for 2007. Available at www.who.int/classifications/apps/icd/icd10online/. Accessed November 2008.